Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04880863
Status:
COMPLETED
Last Update Posted:
2024-02-22
First Post:
2021-05-03
Brief Title:
Naptumomab Estafenatox NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Sponsor:
NeoTX Therapeutics Ltd
Organization:
NeoTX Therapeutics Ltd
Organization Data
Organization:
NeoTX Therapeutics Ltd
Class:
INDUSTRY
Study ID:
NT-NAP-102-1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
NeoTX Therapeutics Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Translational Drug Development | OTHER |